Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Joe Lyddon who wrote (57011)	6/1/2000 8:34:00 PM
From: labs	Read Replies (1) \| Respond to of 122087

NMPS>>>>>>Not looking so sexy! Matritech has been unprofitable since inception and expects to incur significant operating losses for at least the next several years. For the period from inception to March 31, 2000, the Company incurred a cumulative net loss of approximately $49 million. Product sales revenue decreased to $140,000 from $170,000 for the quarters ended March 31, 2000 and 1999, respectively. The developer of medical diagnostic products said it successfully completed the ``proof of clinical concept'' for its NMP66 blood test for breast cancer and will continue testing. Sales are weak, not looking at making money any time soon. Continually raise funds through financings, such as the excercise of warrants that expire today. Why continue testing???? The results look pretty conclusive to me!!